Catheter-Directed Thrombolysis Market size was over USD 453.2 million in 2023 and is likely to reach USD 931.68 million by 2036, witnessing around 5.7% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of catheter-directed thrombolysis is assessed at USD 473.87 million. The growth of the market is primarily attributed to the increasing prevalence of pulmonary embolism and deep vein thrombosis (DVT) amidst increasing number of stroke issues. For instance, every year approximately 900,010 number of people affected by deep vein thrombosis (DVT) or pulmonary embolism (PE).
Catheter-directed thrombolysis is a prominent treatment to treat blood vessel clots by improving blood flow and deterring tissue damage. Thrombolysis is a sort of minimally invasive endovascular therapy. It primarily includes injecting clot-busting drugs through an intravenous (IV) line or a catheter-directed thrombolysis (CDT) device, which supplies the drugs directly to the blocking sites for anticoagulation. Catheter-directed thrombolysis device consists an X-Ray camera, catheter, special medicines, and a medical device used to disperse blood clots. CDT devices are safer than traditional surgical intervention such as surgical balloon thrombectomy, allowing for shorter hospital stays while reducing patient trauma and health issues.As per the data provided by the National Center for Biotechnology Information, trauma is the major cause of death among young adults and accounts for 10% of all deaths in men and women. Every year, approximately 50 million people visit the emergency department in the United States owing to trauma.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
5.7% |
|
Base Year Market Size (2023) |
USD 453.2 million |
|
Forecast Year Market Size (2036) |
USD 931.68 million |
|
Regional Scope |
|
The global catheter-directed thrombolysis market is segmented and analyzed for demand and supply by end-user intoambulatory surgical centers, hospitals, radiology clinics, and others. Out of these, hospitals segment is estimated to significantly grow over the forecast period owing to theincreasing number of patients of pulmonary embolism, and deep vein thrombosis, and increasing government investments in healthcare sector. Asper the data by the World Bank, the world-wide health expenditure in 2019 was grown to 9.83%.
Our in-depth analysis of the global catheter-directed thrombolysis market includes the following segments:
|
By Delivery Mode |
|
|
By Indication |
|
|
By End-User |
|
Regionally, the global catheter-directed thrombolysis market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is set to account for largest revenue share by 2036, backed by availability of advanced healthcare facilities, increase in healthcare expenditure, and growing disposable income in the region. According to the data released by the Centers for Medicare & Medicaid Services (CMS), in 2020, US national healthcare expenditure expanded 9.7% to USD 4.1 trillion, equivalent to USD 12,530 per person, representing for 19.7% of Gross Domestic Product.
Boston Scientific Corporation (BSC)acquired Obsidio, Inc., a privately-held company that has developed Gel Embolic Material (GEM) technology for embolizing blood vessels in the peripheral circulatory system.
iVascular S.L.U,launched its sergeant peripheral support catheter for patients with peripheral artery disease or challenging anatomy during diagnostic and interventional procedures. The device offers excellent torque capacity and pushability owing to its tapered shaft design.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?